Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.3.1 (
alkaline phosphatase
)
47,916
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Expression of the hominoid-specific
TBC1D3
oncoprotein enhances growth factor receptor signaling and subsequently promotes cellular proliferation and survival. Here we report that
TBC1D3
is degraded in response to growth factor signaling, suggesting that
TBC1D3
expression is regulated by a growth factor-driven negative feedback loop. To gain a better understanding of how
TBC1D3
is regulated, we studied the effects of growth factor receptor signaling on
TBC1D3
post-translational processing and turnover. Using a yeast two-hybrid screen, we identified CUL7, the scaffolding subunit of the CUL7 E3 ligase complex, as a
TBC1D3
-interacting protein. We show that CUL7 E3 ligase ubiquitinates
TBC1D3
in response to serum stimulation. Moreover,
TBC1D3
recruits F-box 8 (Fbw8), the substrate recognition domain of CUL7 E3 ligase, in pull-down experiments and in an in vitro assay. Importantly,
alkaline phosphatase
treatment of
TBC1D3
suppresses its ability to recruit Fbw8, indicating that
TBC1D3
phosphorylation is critical for its ubiquitination and degradation. We conclude that serum- and growth factor-stimulated
TBC1D3
ubiquitination and degradation are regulated by its interaction with CUL7-Fbw8.
...
PMID:Ubiquitination and degradation of the hominoid-specific oncoprotein TBC1D3 is mediated by CUL7 E3 ligase. 2302 30